A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule
Post-Marketing Surveillance (PMS) Study to Evaluate Safety and Efficacy of Zeldox Capsule
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- ADULT
- OLDER_ADULT
- CHILD
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patients diagnosed with schizophrenia
Exclusion Criteria:
- Patients who have known hypersensitivity to any ingredient of the product
- Patients who have had a recent acute myocardial infarction
- Patients who have uncompensated heart failure
- Patients who have conditions with a potential to increase QT interval (QT-interval prolongation or history of QT prolongation; congenital long QT syndrome; use with other drugs known to increase the QT interval; arrhythmias treated with class I and III antiarrhythmic drugs)
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
observational cohort
|
This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Participants for Clinical Global Impression of Severity (CGI-S) Status at Final Visit (up to Week 8) - Intent to Treat Population
Time Frame: Baseline up to Week 8
|
CGI-S is a single-item clinician rated scale to rate the severity of a participant's illness over time.
Scores range from 1 (normal, not ill at all) to 7 (among the most extremely ill); higher score indicates more affected.
|
Baseline up to Week 8
|
|
Number of Participants for Clinical Global Impression of Severity (CGI-S) Status at Final Visit (up to Week 8) - Per Protocol Population
Time Frame: Baseline up to Week 8
|
CGI-S is a single-item clinician rated scale to rate the severity of a participant's illness over time.
Scores range from 1 (normal, not ill at all) to 7 (among the most extremely ill); higher score indicates more affected.
|
Baseline up to Week 8
|
|
Number of Participants for Change From Baseline in Clinical Global Impression - Improvement (CGI-I) at Final Visit (up to Week 8) - ITT
Time Frame: Baseline up to Week 8
|
CGI-I is a single-item clinician rated scale used to assess the participant's improvement or worsening from baseline.
Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse); higher score indicates more affected.
|
Baseline up to Week 8
|
|
Number of Participants for Change From Baseline in Clinical Global Impression - Improvement (CGI-I) at Final Visit (up to Week 8) - PP
Time Frame: Baseline up to Week 8
|
CGI-I is a single-item clinician rated scale used to assess the participant's improvement or worsening from baseline.
Scores range from 1 (very much improved) to 4 (no change) to 7 (very much worse); higher score indicates more affected.
|
Baseline up to Week 8
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change From Baseline in Brief Psychiatric Rating Scale (BPRS ) - Improvement
Time Frame: Baseline up to Week 8
|
BPRS-A: 18-item clinician rated scale to assess somatic concern, anxiety, emotional withdrawal, disorganization, hallucinatory behavior, guilt feelings, suspiciousness, disorientation, tension, mannerisms, posturing, grandiosity, depressive mood, hostility, motor retardation, uncooperativeness, unusual thought content, blunted affect, and excitement.
Ratings anchored to improve consistency for a single rater over time or between raters.
Items rated on 7-point scale 0 (not present) to 6 (extremely severe).
Total score=sum of items (range 0 to 108); higher scores indicate increased pathology.
|
Baseline up to Week 8
|
|
Change From Baseline in Drug Attitude Inventory (DAI-10) - Improvement
Time Frame: Baseline up to Week 8
|
DAI-10: a 10-item scale to assess how the attitude of participants with schizophrenia toward their medications may affect compliance.
Respondents indicate 'true' or 'false' for each item.
An overall calculated score ranges from -10 to 10, where a positive score indicates a positive subjective response (compliant); a negative score indicates non-compliance.
|
Baseline up to Week 8
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Schizophrenia Spectrum and Other Psychotic Disorders
- Bipolar and Related Disorders
- Schizophrenia
- Bipolar Disorder
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Antipsychotic Agents
- Tranquilizing Agents
- Psychotropic Drugs
- Serotonin Agents
- Dopamine Agents
- Serotonin Antagonists
- Dopamine Antagonists
- Ziprasidone
Other Study ID Numbers
Other Study ID Numbers
- A1281140
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.